A new inter partes review, IPR2026-00400, was filed on June 22, 2026, at the Patent Trial and Appeal Board against Thorne Research, Inc. The proceeding is one to watch for companies operating at the intersection of dietary supplements, formulations, and health-focused consumer products, where patent value often turns on how broadly claims are drafted and how well they withstand validity attacks based on published prior art.

At this stage, the publicly available docket information identifies Thorne Research, Inc. as the patent owner, but practitioners should review the petition and related filings to confirm the specific challenged patent, the real parties in interest, and the exact claims at issue as the record develops.

The Patent Trial and Appeal Board’s Final Written Decision in IPR2025-00230 is a useful reminder of how decisively the Board will resolve validity disputes when the petitioner’s prior-art combinations, expert support, and claim construction positions align cleanly with the intrinsic record. In this June 11, 2026 decision, the PTAB concluded the inter partes review on the merits and determined the patentability of the challenged claims under the instituted grounds.

Although each final written decision turns on the particular technology and references at issue, the structure of the Board’s analysis here follows a familiar and important pattern for practitioners.

The Patent Trial and Appeal Board granted institution in IPR2026-00189, finding that the petitioner made the required threshold showing that at least one challenged claim is reasonably likely to be unpatentable. At the institution stage, that is the key question under 35 U.S.C. § 314(a): not whether the patent is ultimately invalid, but whether the petition presents a sufficiently strong merits case to justify full trial before the Board.

Although an institution decision is preliminary, it is often the first meaningful read on how the PTAB views the parties’ invalidity theories, prior art combinations, and claim construction disputes.